Aurora Investment Counsel Has $888,000 Stock Holdings in Cencora, Inc. $COR

Aurora Investment Counsel trimmed its position in Cencora, Inc. (NYSE:COR) by 50.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 2,630 shares of the company’s stock after selling 2,632 shares during the period. Aurora Investment Counsel’s holdings in Cencora were worth $888,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Oakworth Capital Inc. acquired a new position in Cencora during the 4th quarter valued at about $26,000. Elyxium Wealth LLC acquired a new stake in shares of Cencora during the 4th quarter worth approximately $27,000. Archer Investment Corp grew its position in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after buying an additional 47 shares during the period. IAG Wealth Partners LLC bought a new stake in shares of Cencora during the third quarter worth approximately $30,000. Finally, Caitlin John LLC bought a new stake in shares of Cencora during the third quarter worth approximately $31,000. 97.52% of the stock is owned by institutional investors.

Cencora Trading Up 0.0%

Cencora stock opened at $281.56 on Friday. The firm has a 50-day moving average of $289.22 and a 200-day moving average of $327.63. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The company has a market cap of $54.78 billion, a price-to-earnings ratio of 21.59, a P/E/G ratio of 1.52 and a beta of 0.59.

Cencora (NYSE:COR) last released its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same period in the prior year, the firm posted $4.42 EPS. Cencora’s revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, equities analysts expect that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora announced that its board has approved a stock repurchase plan on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 3.9% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its stock is undervalued.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. Cencora’s payout ratio is 18.40%.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Morgan Stanley set a $342.00 price objective on shares of Cencora in a research note on Friday, May 8th. UBS Group upped their target price on shares of Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Evercore set a $360.00 price target on Cencora in a report on Wednesday, April 8th. Barclays dropped their price objective on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Robert W. Baird reduced their target price on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $374.00.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.